Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children’s Oncology Group Study, AREN03B2

Lovvorn HN 3rd, Renfro LA, Benedetti DJ, Kotagal M, Phelps HM, Ehrlich PF, Lo AC, Sandberg JK, Treece AL, Gow KW, Glick RD, Davidoff AM, Cost NG, Dix DB, Fernandez CV, Dome JS, Geller JI, Mullen EA. Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children’s Oncology Group Study, AREN03B2. J Am Coll Surg. 2024 Apr 1;238(4):733-749. doi: 10.1097/XCS.0000000000000999. Epub 2024 Mar 15. PubMed PMID: 38251681; PubMed Central PMCID: PMC11138877.

To review race and ethnic group enrollment and outcomes for Wilms tumor (WT) across all four risk-assigned therapeutic trials from the current era Children’s Oncology Group Renal Tumor Biology and Risk Stratification Protocol, AREN03B2. For WT patients enrolled on AREN03B2 (2006–2019), disease and biologic features, therapeutic study-specific enrollment, and event-free (EFS) and overall (OS) 4-year survival were compared between institutionally reported race and ethnic groups.